Hereditary Hemorrhagic Telangectasia Center of Excellence

HHT Foundation Center of Excellence Badge

In partnership with our HTC, UF has become the most recent Hereditary Hemorrhagic Telangectasia (HHT) Center of Excellence.

In children, HHT presents most frequently as constantly recurring nose bleeds.  In addition, children may develop iron deficiency as a result of frequent bleeding. We screen for these things during our clinic visits. HHT is most commonly caused by a mutation in the either the ENG or ACVRL-1 (or ALK-1) genes which account for about 80% of cases. There are other genes that have been associated with HHT including SMAD4, GDF2, and RASA1. It occurs at a rate of 1 in 5,000 people. It is generally inherited in an autosomal dominant fashion, so both boys and girls can have it and there is not a carrier, or silent, state. HHT is associated with bleeding caused by abnormal blood vessel development where essentially an artery grows right into a vein without becoming a capillary first (an arteriovenous malformation or AVM). A telangiectasia looks like a web of small vessels under the surface of the skin because it is an AVM that occurs right underneath the skin. This transition point of the vessels is more fragile and because of higher pressures exerted directly by the arterial circulation the vein is more prone to rupturing and bleeding. Other AVM in the lungs and brain may  also be found during childhood and may occasionally rupture. Diagnosis is made with genetic testing and/or based on clinical criteria (Curacao Critera: 2-3 or more including nosebleeds, telangiectasia, AVM, and family history). Treatment is supportive with a reliance on local control, antifibrinolytic therapies (aminocaproic acid and tranexamic acid), nasal cautery and antiangiogenic drugs. Dr. Ali Ataya is leading a study to look at the effectiveness of antiangiogenic therapy.